# Clonal Complexity Defines Distinct Tumor‐Intrinsic Biology and Prognosis in Diffuse Large B‐Cell Lymphoma

**Authors:** Takahiro Haeno, Kazuko Sakai, Shuji Minamoto, Daiki Nakatsu, Marco A. De Velasco, Shinya Rai, Hirokazu Tanaka, Itaru Matsumura, Kazuto Nishio

PMC · DOI: 10.1002/cam4.71597 · Cancer Medicine · 2026-02-02

## TL;DR

High genetic diversity within diffuse large B-cell lymphoma tumors, especially in the ABC subtype, is linked to worse survival and more aggressive behavior.

## Contribution

The study identifies clonal complexity as a tumor-intrinsic predictor of prognosis and biology in DLBCL, particularly in the ABC subtype.

## Key findings

- Poly-CC DLBCL tumors show worse event-free survival compared to monoclonal tumors.
- Poly-CC tumors exhibit upregulated cell cycle pathways and higher Ki-67 positivity.
- Poly-ABC tumors have more pathogenic mutations and distinct transcriptional states compared to Mono-ABC tumors.

## Abstract

Intratumor heterogeneity (ITH), characterized by the coexistence of genetically distinct subclones within a tumor, has been associated with adverse clinical outcomes in various cancers. However, the clinical and biological implications of ITH in diffuse large B‐cell lymphoma (DLBCL) are still incompletely understood.

In this study, we applied a SNP‐array–based approach to assess the clonal complexity in formalin‐fixed, paraffin‐embedded tumor specimens obtained from newly diagnosed patients with advanced‐stage DLBCL (n = 74) by calculating the clonal composition (CC) number.

Patients with Poly‐CC tumors (CC ≥ 1), which accounted for 79.7% of the cases, had a 5‐year event‐free survival rate of 38.9%, compared with 69.1% in those with Mono‐CC tumors (CC = 0) (Log‐rank p = 0.0520). This association reached statistical significance in the activated B‐cell (ABC) subtype (n = 35, Log‐rank p = 0.0450) but not in the germinal center B‐cell (GCB) subtype (n = 30, Log‐rank p = 0.910). Gene set enrichment analysis revealed upregulation of cell cycle–related pathways in Poly‐CC tumors, consistent with the significantly higher Ki‐67 positivity rate than in Mono‐CC tumors, as confirmed by immunohistochemistry (p = 0.00227). Within the ABC subtype, Poly‐CC (Poly‐ABC) tumors exhibited more differentiated transcriptional states and enrichment of IRF4‐associated gene signatures as compared with Mono‐CC (Mono‐ABC) tumors. Conversely, IFN‐γ and IFN‐α response pathways and the IL‐6/JAK‐STAT3 signaling pathway were markedly suppressed in the Poly‐ABC tumors. Furthermore, Poly‐ABC tumors carried a significantly higher number of pathogenic mutations as compared with Mono‐ABC tumors (p = 0.0147).

These results suggest that clonal complexity captures tumor‐intrinsic features and biological diversity in DLBCL, especially in the ABC subtype, offering novel insights into the disease pathogenesis.

High intratumor heterogeneity in DLBCL is associated with reduced event‐free survival, particularly in the ABC subtype. Tumors with high clonal composition exhibit more aggressive biological behavior compared to monoclonal tumors in the ABC subtype of DLBCL.

## Linked entities

- **Genes:** IRF4 (interferon regulatory factor 4) [NCBI Gene 3662]
- **Diseases:** diffuse large B-cell lymphoma (MONDO:0018905), DLBCL (MONDO:0018905)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, KMT2D (lysine methyltransferase 2D) [NCBI Gene 8085] {aka AAD10, ALR, BCAHH, CAGL114, KABUK1, KMS}, NPR2 (natriuretic peptide receptor 2) [NCBI Gene 4882] {aka AMDM, ANPRB, ANPb, ECDM, GC-B, GCB}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TNFRSF14 (TNF receptor superfamily member 14) [NCBI Gene 8764] {aka ATAR, CD270, HVEA, HVEM, LIGHTR, TR2}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CD79B (CD79b molecule) [NCBI Gene 974] {aka AGM6, B29, IGB, Igbeta}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, ABCB6 (ATP binding cassette subfamily B member 6 (LAN blood group)) [NCBI Gene 10058] {aka ABC, LAN, MTABC3, PRP, umat}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CREBBP (CREB binding lysine acetyltransferase) [NCBI Gene 1387] {aka CBP, KAT3A, MKHK1, RSTS, RSTS1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, PIM1 (Pim-1 proto-oncogene, serine/threonine kinase) [NCBI Gene 5292] {aka PIM}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** death (MESH:D003643), disease (MESH:D004194), B-cell lymphomas (MESH:D016393), ABC tumors (MESH:D015448), non-Hodgkin lymphoma (MESH:D008228), complement (MESH:D007153), lung adenocarcinoma (MESH:D000077192), Poly-CC ABC tumors (MESH:D000090267), Breast Cancer (MESH:D001943), inflammation (MESH:D007249), COO (MESH:D002292), TPM (OMIM:602482), DLBCL (MESH:D016403), GCB tumors (MESH:D054331), Lymphoma (MESH:D008223), CC (MESH:D058617), BAF (MESH:D006509), HCC (MESH:D006528), ovarian cancer (MESH:D010051), MATH (MESH:D009369)
- **Chemicals:** CVP (MESH:C034588), HE (MESH:D006371), R (MESH:D001120), eosin (MESH:D004801), vincristine (MESH:D014750), Rituximab (MESH:D000069283), pirarubicin (MESH:C027260), hematoxylin (MESH:D006416), paraffin (MESH:D010232), formalin (MESH:D005557), polatuzumab vedotin (MESH:C000600736), CHOP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376]
- **Mutations:** L265P, T790M

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12863995/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12863995/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12863995/full.md

---
Source: https://tomesphere.com/paper/PMC12863995